Compounds > fingolimod hydrochloride
Page last updated: 2024-09-02

fingolimod hydrochloride and Co-infection

fingolimod hydrochloride has been researched along with Co-infection in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Hartung, HP; Kleinschnitz, C; Mausberg, AK; Meyer Zu Hörste, G; Stettner, M; Szepanowski, F; Warnke, C1

Reviews

1 review(s) available for fingolimod hydrochloride and Co-infection

ArticleYear
Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology.
    CNS drugs, 2021, Volume: 35, Issue:11

    Topics: Age Factors; Alemtuzumab; Animals; Coinfection; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunoglobulin G; Immunologic Factors; Immunosuppressive Agents; Immunotherapy; Infections; Natalizumab; Neurology; Risk Factors; Rituximab

2021